PL3589636T3 - Sposoby wytwarzania inhibitorów acc i ich form stałych - Google Patents

Sposoby wytwarzania inhibitorów acc i ich form stałych

Info

Publication number
PL3589636T3
PL3589636T3 PL18712343.5T PL18712343T PL3589636T3 PL 3589636 T3 PL3589636 T3 PL 3589636T3 PL 18712343 T PL18712343 T PL 18712343T PL 3589636 T3 PL3589636 T3 PL 3589636T3
Authority
PL
Poland
Prior art keywords
processes
solid forms
acc inhibitors
preparing
preparing acc
Prior art date
Application number
PL18712343.5T
Other languages
English (en)
Inventor
Michael Geier
Luke Humphreys
Norihiro Ikemoto
Sean Liew
Henry Morrison
Mark E. Scott
Vimal Varghese
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3589636T3 publication Critical patent/PL3589636T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/293—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/08—Preparation of carboxylic acid nitriles by addition of hydrogen cyanide or salts thereof to unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/08—Preparation of carboxylic acids or their salts, halides or anhydrides from nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C07C59/13—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/29—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/05—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in nitriles (3.5.5)
    • C12Y305/05001—Nitrilase (3.5.5.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL18712343.5T 2017-03-03 2018-03-02 Sposoby wytwarzania inhibitorów acc i ich form stałych PL3589636T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762466915P 2017-03-03 2017-03-03
US201762553300P 2017-09-01 2017-09-01
PCT/US2018/020747 WO2018161022A1 (en) 2017-03-03 2018-03-02 Processes for preparing acc inhibitors and solid forms thereof

Publications (1)

Publication Number Publication Date
PL3589636T3 true PL3589636T3 (pl) 2024-02-19

Family

ID=61692103

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18712343.5T PL3589636T3 (pl) 2017-03-03 2018-03-02 Sposoby wytwarzania inhibitorów acc i ich form stałych

Country Status (11)

Country Link
US (3) US10519165B2 (pl)
EP (2) EP4273132A3 (pl)
JP (4) JP2020509047A (pl)
KR (3) KR102485620B1 (pl)
CN (2) CN115449529A (pl)
AU (3) AU2018227588B2 (pl)
CA (2) CA3053956C (pl)
ES (1) ES2963841T3 (pl)
PL (1) PL3589636T3 (pl)
TW (1) TWI785016B (pl)
WO (1) WO2018161022A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3191470T (pt) 2015-07-06 2019-06-05 Gilead Sciences Inc Moduladores de cot e métodos para a sua utilização
PL3589636T3 (pl) 2017-03-03 2024-02-19 Gilead Sciences, Inc. Sposoby wytwarzania inhibitorów acc i ich form stałych
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
US10995099B2 (en) * 2017-07-17 2021-05-04 Nanjing Ruijie Pharmatech Co., Ltd. Compounds and their uses as ACC inhibitors
KR20190036705A (ko) * 2017-09-28 2019-04-05 한미약품 주식회사 (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체
US10980810B2 (en) 2017-10-06 2021-04-20 Gilead Sciences, Inc. Combination therapy comprising an ACC inhibitor
CN110950884B (zh) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN111484504B (zh) * 2019-01-25 2024-05-10 南京圣和药业股份有限公司 Acc抑制剂的光学异构体及其应用
CN109810085B (zh) * 2019-04-19 2019-07-19 上海皓元生物医药科技有限公司 Acc抑制剂及其中间体的制备方法
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
WO2021110138A1 (zh) * 2019-12-05 2021-06-10 漳州片仔癀药业股份有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用
ES2965380T3 (es) * 2019-12-05 2024-04-15 Zhangzhou Pien Tze Huang Pharm Forma cristalina como inhibidor de ACC1 y ACC2, y método de preparación de la misma y uso de la misma
KR20220161438A (ko) 2020-03-30 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
WO2021202688A1 (en) 2020-04-02 2021-10-07 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN113968871A (zh) * 2020-07-25 2022-01-25 南京圣和药业股份有限公司 苯基取代类acc抑制剂的晶型
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
KR20230158542A (ko) 2021-03-29 2023-11-20 길리애드 사이언시즈, 인코포레이티드 Khk 억제제
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
JP2025529972A (ja) * 2022-09-02 2025-09-09 レックスファームテック カンパニー リミテッド 新規ベンフォチアミンコリン塩
TWI887826B (zh) * 2022-11-02 2025-06-21 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45574T1 (de) * 1983-01-17 1989-09-15 Pfizer Aldosereduktasehemmende 5-(2alkoxyphenyl)thiazolidinedione.
DE3332562A1 (de) * 1983-09-09 1985-03-28 Basf Ag, 6700 Ludwigshafen 2-oxocarbonsaeurereduktase, ihre herstellung und verwendung
ES2059817T3 (es) * 1988-06-06 1994-11-16 Ciba Geigy Ag Procedimiento para la preparacion de hidroxiacidos.
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
DE10347888A1 (de) * 2003-10-10 2005-06-30 Degussa Ag Verfahren zur Herstellung von enantiomerenangereicherten alpha-Hydroxycarbonsäuren bzw. -amide
JPWO2007026860A1 (ja) * 2005-09-02 2009-03-12 第一ファインケミカル株式会社 光学活性α−ヒドロキシカルボン酸の製造方法
JP5057727B2 (ja) * 2006-09-06 2012-10-24 三菱レイヨン株式会社 ヒドロキシニトリルリアーゼ遺伝子、ニトリラーゼ遺伝子を含む形質転換体、並びにそれを用いたα−ヒドロキシカルボン酸の製造法
JP2009027968A (ja) * 2007-07-26 2009-02-12 Mitsubishi Rayon Co Ltd 新規なニトリラーゼ
JP2010022314A (ja) * 2008-07-23 2010-02-04 Mitsubishi Rayon Co Ltd カルボン酸の製造方法
KR102033806B1 (ko) 2011-11-11 2019-10-17 길리어드 아폴로, 엘엘씨 Ａｃｃ 억제제 및 이의 용도
CN102559781B (zh) * 2011-12-15 2013-08-21 重庆大学 一种制备r-扁桃酸的方法
JP6096010B2 (ja) * 2013-03-14 2017-03-15 株式会社ダイセル 酵素架橋凝集体、及びこれを備えるマイクロリアクター
CN105567652B (zh) * 2014-10-14 2019-06-11 上海弈柯莱生物医药科技有限公司 一种酮还原酶及其在不对称合成手性羟基化合物中的应用
AU2017226267B2 (en) * 2016-03-02 2021-06-24 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
CN108341830B (zh) * 2017-01-22 2021-03-02 广东东阳光药业有限公司 噻吩并嘧啶衍生物及其在药物中的应用
JP2020509038A (ja) 2017-03-03 2020-03-26 ギリアド アポロ， エルエルシー 殺真菌剤化合物を調製するための方法
PL3589636T3 (pl) 2017-03-03 2024-02-19 Gilead Sciences, Inc. Sposoby wytwarzania inhibitorów acc i ich form stałych
KR20190036705A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체
CN109810085B (zh) * 2019-04-19 2019-07-19 上海皓元生物医药科技有限公司 Acc抑制剂及其中间体的制备方法

Also Published As

Publication number Publication date
AU2021200966B2 (en) 2022-09-08
AU2018227588B2 (en) 2021-01-21
JP2024102196A (ja) 2024-07-30
KR102485620B1 (ko) 2023-01-09
US20210024537A1 (en) 2021-01-28
CN115449529A (zh) 2022-12-09
US20180298025A1 (en) 2018-10-18
JP2021091736A (ja) 2021-06-17
US11279710B2 (en) 2022-03-22
US10519165B2 (en) 2019-12-31
KR20190125384A (ko) 2019-11-06
WO2018161022A1 (en) 2018-09-07
JP2020509047A (ja) 2020-03-26
CN110382503B (zh) 2022-07-19
EP4273132A2 (en) 2023-11-08
EP3589636C0 (en) 2023-09-13
ES2963841T3 (es) 2024-04-02
EP3589636A1 (en) 2020-01-08
KR102424042B1 (ko) 2022-07-22
TWI785016B (zh) 2022-12-01
US20200199147A1 (en) 2020-06-25
CA3053956C (en) 2024-04-23
EP3589636B1 (en) 2023-09-13
AU2018227588A1 (en) 2019-08-22
JP2022188200A (ja) 2022-12-20
CN110382503A (zh) 2019-10-25
AU2021200966A1 (en) 2021-03-11
CA3053956A1 (en) 2018-09-07
KR102308412B1 (ko) 2021-10-05
US10745412B2 (en) 2020-08-18
KR20210120141A (ko) 2021-10-06
AU2022233950B2 (en) 2024-02-29
TW201835090A (zh) 2018-10-01
CA3137479A1 (en) 2018-09-07
JP7155315B2 (ja) 2022-10-18
AU2022233950A1 (en) 2022-10-13
KR20220104845A (ko) 2022-07-26
EP4273132A3 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
PL3589636T3 (pl) Sposoby wytwarzania inhibitorów acc i ich form stałych
IL258636A (en) Acc inhibitors and uses thereof
PL3380479T3 (pl) Triazolowe inhibitory acc i ich zastosowania
SI3380480T1 (sl) Pirazolni inhibitorji ACC in uporabe le-teh
PL3718370T3 (pl) Sposoby i powiązane urządzenia służące do realizacji funkcji multi-connectivity
GB201706579D0 (en) Systems and methods for phone-as-a-key range extension
HUE053175T2 (hu) ACC-gátló észterek és azok alkalmazása
IL261414B (en) Solid state forms of venetoclax and processes for preparation of venetoclax
GB2598068B (en) System and method for geofencing
SG11201912231VA (en) Systems and methods for blockchain-dependent operation sets
ZA201701922B (en) Range finding apparatus and system
SG10202108617XA (en) Method and system for starting application
PT3580219T (pt) Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam
ZA201907136B (en) Ip6k inhibitors
SMT202100496T1 (it) Nucleotidi di beta-nicotinato estere e processi per preparare gli stessi
GB2536353B (en) Methods and systems for slurry coating
SG10201602193WA (en) Systems and methods for mass calibration
PT3107733T (pt) Método e instalação para o revestimento de produtos de rolos
SG11201607442SA (en) Synthetic antenna sonar and method for forming synthetic antenna beams
ZA201801964B (en) Systems and methods for product authentication
IL274550A (en) Dopamine-B-hydroxylase inhibitors
EP3137447A4 (en) Inhibitors of creatine transport and uses thereof
ZA201903950B (en) Method for the manufacture of efavirenz
PL3288930T3 (pl) Sposób i urządzenie do wytwarzania laktydu
PL3608324T3 (pl) Sposób wytwarzania 2-arylomalonoamidu i zastosowania tego sposobu